Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

Gross profit increased 20.8% in 2024 compared to 2023. SINGAPORE, May 16, 2025 (GLOBE NEWSWIRE) -- Concorde International Group Ltd. (NASDAQ: CIGL) ("Concorde” or the "Company), ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral ...

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage. This abnormal wound-healing response distorts the liver's structure, ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in ...

SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotech company whose stock has declined nearly 78% over the past year according to InvestingPro data, has presented ...

Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Basic Materials, Healthcare and Utilities ...